MX2023003996A - Compuestos de 7-azaindol para la inhibicion de tirosina cinasas bcr-abl. - Google Patents
Compuestos de 7-azaindol para la inhibicion de tirosina cinasas bcr-abl.Info
- Publication number
- MX2023003996A MX2023003996A MX2023003996A MX2023003996A MX2023003996A MX 2023003996 A MX2023003996 A MX 2023003996A MX 2023003996 A MX2023003996 A MX 2023003996A MX 2023003996 A MX2023003996 A MX 2023003996A MX 2023003996 A MX2023003996 A MX 2023003996A
- Authority
- MX
- Mexico
- Prior art keywords
- bcr
- inhibition
- tyrosine kinases
- abl tyrosine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063087780P | 2020-10-05 | 2020-10-05 | |
| PCT/US2021/071692 WO2022076973A1 (en) | 2020-10-05 | 2021-10-04 | 7-azaindole compounds for inhibition of bcr-abl tyrosine kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003996A true MX2023003996A (es) | 2023-06-15 |
Family
ID=81125544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003996A MX2023003996A (es) | 2020-10-05 | 2021-10-04 | Compuestos de 7-azaindol para la inhibicion de tirosina cinasas bcr-abl. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240043420A1 (enExample) |
| EP (1) | EP4225741A4 (enExample) |
| JP (1) | JP7826325B2 (enExample) |
| KR (1) | KR20230104782A (enExample) |
| CN (1) | CN116438182A (enExample) |
| IL (1) | IL301740A (enExample) |
| MX (1) | MX2023003996A (enExample) |
| WO (1) | WO2022076973A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3196620A1 (en) | 2020-10-05 | 2022-04-14 | Enliven Therapeutics, Inc. | 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases |
| WO2023081637A1 (en) * | 2021-11-02 | 2023-05-11 | Enliven Therapeutics, Inc. | Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 |
| CN116063212B (zh) * | 2023-01-28 | 2023-06-27 | 山东国邦药业有限公司 | 一种4-苯硫基-1,2-苯二胺的制备方法 |
| CN119954701B (zh) * | 2024-06-18 | 2026-06-16 | 青岛润农化工有限公司 | 一种丁醚脲的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0330043D0 (en) * | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
| JP5122280B2 (ja) | 2004-06-30 | 2013-01-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼのインヒビターとして有用なアザインドール |
| EP2325184A1 (en) * | 2004-06-30 | 2011-05-25 | Vertex Pharmceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
| NZ553267A (en) | 2004-07-27 | 2010-09-30 | Sgx Pharmaceuticals Inc | Pyrrolo-pyridine kinase modulators |
| US8604055B2 (en) * | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| JP2007099640A (ja) | 2005-09-30 | 2007-04-19 | Tsumura & Co | 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物 |
| FR2941948B1 (fr) * | 2009-02-12 | 2013-04-05 | Nova Decision | Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src |
| FR3000492B1 (fr) * | 2012-12-28 | 2015-09-11 | Oribase Pharma | Nouveaux derives azaindole en tant qu'inhibiteurs multikinases |
| US10696687B2 (en) * | 2015-08-20 | 2020-06-30 | Changzhou Jiekai Pharmatech Co., Ltd. | Pyrazolo fused heterocyclic compounds as ERK inhibitors |
-
2021
- 2021-10-04 WO PCT/US2021/071692 patent/WO2022076973A1/en not_active Ceased
- 2021-10-04 US US18/030,205 patent/US20240043420A1/en active Pending
- 2021-10-04 JP JP2023545895A patent/JP7826325B2/ja active Active
- 2021-10-04 KR KR1020237015285A patent/KR20230104782A/ko active Pending
- 2021-10-04 EP EP21878712.5A patent/EP4225741A4/en active Pending
- 2021-10-04 IL IL301740A patent/IL301740A/en unknown
- 2021-10-04 MX MX2023003996A patent/MX2023003996A/es unknown
- 2021-10-04 CN CN202180081403.1A patent/CN116438182A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230104782A (ko) | 2023-07-10 |
| CN116438182A (zh) | 2023-07-14 |
| WO2022076973A1 (en) | 2022-04-14 |
| US20240043420A1 (en) | 2024-02-08 |
| IL301740A (en) | 2023-05-01 |
| EP4225741A4 (en) | 2024-10-30 |
| EP4225741A1 (en) | 2023-08-16 |
| JP7826325B2 (ja) | 2026-03-09 |
| JP2023545219A (ja) | 2023-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003995A (es) | Compuestos de 5-y 6-azaindol para la inhibicion de tirosina cinasas bcr-abl. | |
| MX2026002575A (es) | Inhibidores de sos1 para uso en el tratamiento de canceres hematologicos positivos para el cromosoma filadelfia | |
| MX2021003517A (es) | Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso. | |
| ZA202201364B (en) | Deuterated compounds for use in the treatment of cancer | |
| PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
| PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| MX2021003478A (es) | Compuestos utiles como inhibidores de cinasa. | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| PH12020500343A1 (en) | Pyruvate kinase activators for use in treating blood disorders | |
| EA201992322A3 (ru) | Соединения и композиции для лечения гематологических расстройств | |
| MX2023010882A (es) | Compuestos y composiciones para el tratamiento de trastornos hematológicos. | |
| JO3794B1 (ar) | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون | |
| NZ722326A (en) | Tricyclic compounds as anticancer agents | |
| AR067505A1 (es) | Derivados de pirimidinil-piridazinona | |
| WO2017216772A3 (en) | Methods and compositions for treating breast and prostate cancer | |
| EP4338802A3 (en) | Tyk2 inhibitors, uses, and methods for production thereof | |
| TN2017000459A1 (en) | 5'-substituted nucleoside analogs | |
| AU2015314007B2 (en) | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers | |
| MX2020003126A (es) | Derivados de iminopirimidina ciclicos como inhibidores de cinasa. | |
| PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
| PH12020551853A1 (en) | Axl kinase inhibitors and use of the same | |
| DOP2011000129A (es) | 1h-imidazol-2-il-piperidin-1-il como inhibidores de cinasa akt y p70 s6 | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها |